Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980210 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL982824 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL983250 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL982044 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL982532 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL984576 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL983446 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL133829 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL982845 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL352666 | 1.00 | THRB (0.42) | THRBTSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY | 2024-05-30 | — | — | US | claimed |
| EP-4333859-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | Emory University (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | claimed |
| EP-4161596-A1 | NANOFIBROUS MATERIAL PARTICULARLY FOR TOPICAL USE IN THERAPIES | Univerzita Karlova (CZ) | 2023-04-12 | — | — | EP | claimed |
| US-11135237-B2 | Lipophosphonoxins of second generation, and their use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2021-10-05 | — | — | US | claimed |
| US-20210220383-A1 | LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2021-07-22 | — | — | US | claimed |
| EP-3125894-B1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-09 | — | — | EP | claimed |
| EP-3599844-A1 | ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS | University of Massachusetts (US) | 2020-02-05 | — | — | EP | claimed |
| WO-2019198923-A1 | MICROSTRUCTURE FOR TRANSCUTANEOUS AND INTRACUTANEOUS DRUG DELIVERY OF CYCLOSPORIN A (CSA) | 가천대학교 산학협력단 | 2019-10-17 | — | — | WO | claimed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | claimed |
| EP-2443130-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | Centre National de la Recherche Scientifique (FR) | 2012-04-25 | — | — | EP | claimed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | claimed |
| EP-2270021-A1 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability | Centre National de la Recherche Scientifique (FR) | 2011-01-05 | — | — | EP | claimed |
| WO-2010146127-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-23 | — | — | WO | claimed |
| US-20090215726-A1 | Phosphono-Pent-2-en-1-yl Nucleosides and Analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-27 | — | — | US | claimed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | claimed |
| EP-1866319-A1 | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006137953-A1 | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | THE REGENTS OF THE UNIVERISITY OF CALIFORNIA (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006076015-A2 | 1-[2-(PHOSPHONOMETHOXY)ETHYL]-CYTOSINE AND ANALOGS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | THRB 2027/4885TSHR 3232/4885MEN1 2049/4885 |
| US-20090215726-A1 | Phosphono-Pent-2-en-1-yl Nucleosides and Analogs | PNP, TYMP, ENPP1 | THRB 2233/4885TSHR 3345/4885MEN1 1848/4885 |
| US-11135237-B2 | Lipophosphonoxins of second generation, and their use | PLA2G1B, PLA2G2E, PLA2G4C | THRB 2528/4885TSHR 1768/4885MEN1 1905/4885 |
| US-20210220383-A1 | LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE | PLA2G1B, PLA2G2E, PLA2G4C | THRB 2528/4885TSHR 1768/4885MEN1 1905/4885 |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | PNP, NTPCR, TYMP | THRB 3281/4885TSHR 3703/4885MEN1 3240/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | THRB 3403/4885TSHR 3640/4885MEN1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.